Quick SearchStructure Search
Prous.com
Journals Home
Drugs of the Future
on the Web
Drugs of the Future
Information
My
Profile
Contact
Us
Drugs of the Future
Register or sign in

 
  
Drugs Fut 2005, 30(1): 7
ISSN 0377-8282
Copyright 2005 Prous Science
CCC: 0377-8282
DOI: 10.1358/dof.2005.030.01.871476		 
 
Bicifadine
Sorbera, L.A., Castaner, J., Leeson, P.A.		 
 
Although a multitude of agents have been developed and marketed for pain management, an effective treatment for chronic pain has not yet been found. Opioid analgesics have been used for thousands of years to treat pain. However, they are not effective in the treatment of all types of chronic pain and can be associated with adverse events, tolerance and dependency. The development of nonopioid therapeutics remains a priority for researchers in the search for effective long-term therapy of chronic pain states. The 1-phenyl-3-azabicyclo[3.1.0]hexane bicifadine is a particularly attractive novel nonopioid analgesic. This NMDA antagonist, which is also an inhibitor of both the norepinephrine and serotonin transporters, was shown to have a non-narcotic profile and potent analgesic activity in vivo. The clinical efficacy of bicifadine has also been demonstrated as a treatment for postoperative dental pain, postbunionectomy pain and chronic lower back pain. Bicifadine is undergoing phase III clinical development for the treatment of acute pain and chronic lower back pain.


Full Text: HTML, PDF 		 
  



© 2008 Prous Science, S.A.U. or its licensors. All rights reserved.
Legal Information.